Srikala Sridhar, MD, MSc, FRCPC

Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC

Srikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.

Srikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.

Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.

Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.

Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.

Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.

Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.

Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.